Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship

Sruthi Selvakumar, Angela Liu, Shruti Chaturvedi

Research output: Contribution to journalReview articlepeer-review


Advances in diagnosis and treatment have dramatically improved survival of acute immune thrombotic thrombocytopenic purpura (iTTP) and iTTP has evolved from an acute fatal condition to a chronic relapsing disorder. In addition to the risk of iTTP relapse, iTTP survivors are at risk of multiple adverse health outcomes including higher than expected rates of all-cause mortality, increased rates of stroke and other cardiovascular disease, and higher rates of morbidities such as obesity, hypertension, and autoimmune disorders. iTTP survivors also report neurocognitive impairment, depression, and reduced quality of life. Women with iTTP are at risk for recurrent iTTP, preeclampsia, and other maternal and fetal complications in subsequent pregnancies. ADAMTS13 activity during clinical remission has emerged as an important targetable risk factor for iTTP relapse and other outcomes including stroke and all-cause mortality. This review summarizes current literature regarding the epidemiology and potential mechanisms for adverse long-term sequelae of iTTP, outlines current best practices in iTTP survivorship care, and highlights a research agenda to improve long-term iTTP outcomes.

Original languageEnglish
Article number1137019
JournalFrontiers in Medicine
StatePublished - 2023


  • ADAMTS13
  • rare disease
  • survivorship
  • thrombotic microangiopathy
  • thrombotic thrombocytopenic purpura


Dive into the research topics of 'Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship'. Together they form a unique fingerprint.

Cite this